New small molecules that target cancer-causing proteins
Small Molecule MYC Degraders as Novel Cancer Therapeutic Agents
This study is looking for new ways to help fight certain cancers by creating small molecules that can break down MYC proteins, which help tumors grow, so that patients can have better and safer treatment options.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stemsynergy Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Miami, United States) |
| Project ID | NIH-10933575 on NIH RePORTER |
What this research studies
This research focuses on developing small molecules that can degrade MYC proteins, which are crucial for the growth of many cancers. The approach involves targeting the interaction between MYC proteins and Aurora A, a kinase that helps MYC evade degradation. By creating compounds that can effectively degrade these proteins, the research aims to inhibit tumor growth in cancers that depend on MYC. Patients may benefit from new treatment options that are both effective and have a favorable safety profile.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with cancers that are dependent on MYC proteins.
Not a fit: Patients with cancers not driven by MYC proteins may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative therapies for patients with MYC-dependent cancers.
How similar studies have performed: Other research has shown promise in targeting MYC proteins, but this specific approach with small molecule degraders is relatively novel.
Where this research is happening
Miami, United States
- Stemsynergy Therapeutics, INC. — Miami, United States (Active)
Researchers
- Principal investigator: Fei, Dennis Liang — Stemsynergy Therapeutics, INC.
- Study coordinator: Fei, Dennis Liang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.